Amplica Bio, Inc. — SEC Form D Filing
Amplica Bio, Inc. filed an SEC Form D on September 11, 2026, reporting $30K raised in Biotechnology.
Form D filing details
- Filing
- SEC Form D
- Filing date
- September 11, 2026
- Amount reported
- $30K
- Round stage
- Series B+
- Industry
- Biotechnology
- Website
- https://amplificabio.com/
What the company does
Securities: Equity, Simple Agreement for Future Equity (SAFE). Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Millions of men and women suffer from hair loss, specifically androgenic alopecia, and there is a significant unmet need for safe and effective products that can promote new hair growth.
Solution
Amplifica is developing novel treatments, including unique signaling molecules and a lead compound AMP-303, to stimulate hair follicles to regrow hair.
Why now
Advances in understanding hair biology and signaling pathways, coupled with a persistent market demand for effective hair regrowth solutions, create an opportune moment for novel biopharmaceutical treatments.
Verdict
This cleared because the biological mechanism promised a novel, durable solution to a widespread, well-understood condition, not because of demonstrated clinical efficacy or market traction. Investors were implicitly betting on the company's ability to navigate preclinical and early clinical development with a clear biological premise, targeting a consumer-driven market with high willingness to pay. However, the early-stage nature and reliance on a single lead compound limited upside, as success was entirely dependent on a protracted, capital-intensive R&D pipeline rather than rapid market penetration.
Source: SEC EDGAR Form D filing